Cargando…
Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes
Objective: To evaluated the prognostic ability of several serum cytokines in clinically isolated syndrome (CIS) patients regarding second events and conversion to multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). Methods: We enrolled 69 CIS patients whose serum samples were...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579832/ https://www.ncbi.nlm.nih.gov/pubmed/31244763 http://dx.doi.org/10.3389/fneur.2019.00604 |
_version_ | 1783427912374943744 |
---|---|
author | Wei, Yuzhen Chang, Haoxiao Feng, Hao Li, Xindi Zhang, Xinghu Yin, Linlin |
author_facet | Wei, Yuzhen Chang, Haoxiao Feng, Hao Li, Xindi Zhang, Xinghu Yin, Linlin |
author_sort | Wei, Yuzhen |
collection | PubMed |
description | Objective: To evaluated the prognostic ability of several serum cytokines in clinically isolated syndrome (CIS) patients regarding second events and conversion to multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). Methods: We enrolled 69 CIS patients whose serum samples were collected during the acute phase of the first onset before immunotherapy. Fifteen other non-inflammatory neurological disorder (OND) patients were also included. The serum levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IL-13, IL-17A, IL-21, IL-23, interferon-γ (IFN-γ), and transforming growth factor beta 1 (TGF-β1) were measured using the human cytokine multiplex assay or ELISA. Patients were seen every 3–6 months. Unscheduled visits occur in case of exacerbations. Clinical measures of disease progression were recorded. Results: Twenty CIS cases had second events during follow-up at a mean time of 15.3 ± 9.9 months. Serum IL-10 levels were significantly lower in CIS patients who relapsed compared to patients who did not. Low serum IL-10 levels were associated with higher risk and shorter times to second events. In clinical correlations, a significantly higher CSF white blood cells count, number of T2 lesions, and gadolinium-enhancing (Gd+) lesions in baseline MRI were found in the low serum IL-10 level group. Of the 20 relapsed cases, seven converted to MS, and eight converted to NMOSD. No significant differences were found in any cytokine levels between these patients at first onset. Conclusions: These findings support using serum IL-10 as a biomarker associated with the risk of relapse and the time to second events in patients with CIS. However, serum cytokine levels can not differentiate between the conversion from CIS to MS or NMOSD. |
format | Online Article Text |
id | pubmed-6579832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65798322019-06-26 Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes Wei, Yuzhen Chang, Haoxiao Feng, Hao Li, Xindi Zhang, Xinghu Yin, Linlin Front Neurol Neurology Objective: To evaluated the prognostic ability of several serum cytokines in clinically isolated syndrome (CIS) patients regarding second events and conversion to multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD). Methods: We enrolled 69 CIS patients whose serum samples were collected during the acute phase of the first onset before immunotherapy. Fifteen other non-inflammatory neurological disorder (OND) patients were also included. The serum levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IL-13, IL-17A, IL-21, IL-23, interferon-γ (IFN-γ), and transforming growth factor beta 1 (TGF-β1) were measured using the human cytokine multiplex assay or ELISA. Patients were seen every 3–6 months. Unscheduled visits occur in case of exacerbations. Clinical measures of disease progression were recorded. Results: Twenty CIS cases had second events during follow-up at a mean time of 15.3 ± 9.9 months. Serum IL-10 levels were significantly lower in CIS patients who relapsed compared to patients who did not. Low serum IL-10 levels were associated with higher risk and shorter times to second events. In clinical correlations, a significantly higher CSF white blood cells count, number of T2 lesions, and gadolinium-enhancing (Gd+) lesions in baseline MRI were found in the low serum IL-10 level group. Of the 20 relapsed cases, seven converted to MS, and eight converted to NMOSD. No significant differences were found in any cytokine levels between these patients at first onset. Conclusions: These findings support using serum IL-10 as a biomarker associated with the risk of relapse and the time to second events in patients with CIS. However, serum cytokine levels can not differentiate between the conversion from CIS to MS or NMOSD. Frontiers Media S.A. 2019-06-11 /pmc/articles/PMC6579832/ /pubmed/31244763 http://dx.doi.org/10.3389/fneur.2019.00604 Text en Copyright © 2019 Wei, Chang, Feng, Li, Zhang and Yin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Wei, Yuzhen Chang, Haoxiao Feng, Hao Li, Xindi Zhang, Xinghu Yin, Linlin Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes |
title | Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes |
title_full | Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes |
title_fullStr | Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes |
title_full_unstemmed | Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes |
title_short | Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes |
title_sort | low serum interleukin-10 is an independent predictive factor for the risk of second event in clinically isolated syndromes |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579832/ https://www.ncbi.nlm.nih.gov/pubmed/31244763 http://dx.doi.org/10.3389/fneur.2019.00604 |
work_keys_str_mv | AT weiyuzhen lowseruminterleukin10isanindependentpredictivefactorfortheriskofsecondeventinclinicallyisolatedsyndromes AT changhaoxiao lowseruminterleukin10isanindependentpredictivefactorfortheriskofsecondeventinclinicallyisolatedsyndromes AT fenghao lowseruminterleukin10isanindependentpredictivefactorfortheriskofsecondeventinclinicallyisolatedsyndromes AT lixindi lowseruminterleukin10isanindependentpredictivefactorfortheriskofsecondeventinclinicallyisolatedsyndromes AT zhangxinghu lowseruminterleukin10isanindependentpredictivefactorfortheriskofsecondeventinclinicallyisolatedsyndromes AT yinlinlin lowseruminterleukin10isanindependentpredictivefactorfortheriskofsecondeventinclinicallyisolatedsyndromes |